Trinity Biotech plc (NASDAQ: TRIB) (ISE: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced today that the 340B Prime Vendor Program, managed by HealthCare Purchasing Partners International™ (HPPI), has signed an agreement with Trinity Biotech to provide the Uni-Gold™ Recombigen® Rapid HIV antibody test to 340B Prime Vendor participants. There are currently in excess of 12,000 public hospitals, community health centers, clinics, state-operated AIDS programs and other safety-net healthcare providers serving low income and uninsured patients that are eligible for 340B. Previously, rapid HIV testing was only available to these grantees through a special bulk purchase program administered by the Centers for Disease Control (CDC).
